Amgen (AMGN)
(Delayed Data from NSDQ)
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $231.10, moving -1.39% from the previous trading session.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $228.59, moving +1.5% from the previous trading session.
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.
The Zacks Analyst Blog Highlights NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen
by Zacks Equity Research
NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen are included in this blog.
Top Stock Reports for NVIDIA, Novartis & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Novartis AG (NVS), and NextEra Energy, Inc. (NEE).
Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
by Zacks Equity Research
Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
by Zacks Equity Research
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals
by Zacks Equity Research
Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.
Will the Rally of These 5 Big Drugmakers Continue in 2022?
by Zacks Equity Research
Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
by Zacks Equity Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up
by Zacks Equity Research
Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.
Stock Market News for Feb 9, 2022
by Zacks Equity Research
U.S. stocks posted solid gains on Tuesday as investors¿¿¿ sentiment got a boost from a batch of robust corporate earnings.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
The Zacks Analyst Blog Highlights Amgen, TakeTwo Interactive, Chegg, Pfizer and BP
by Zacks Equity Research
Amgen, TakeTwo Interactive, Chegg, Pfizer and BP are included in this blog.
Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat
by Mark Vickery
After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.
Amgen (AMGN) Beats Q4 Earnings Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.31% and 0.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
Centene (CNC) Gears Up for Q4 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in total membership.
Incyte (INCY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.